Bupropion

• 

  Subject Areas on Research

  • A 102-center prospective study of seizure in association with bupropion. 
  • A Pilot Trial Examining African American and White Responses to Algorithm-Guided Smoking Cessation Medication Selection in Persons Living with HIV. 
  • A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. 
  • A double-blind comparison of bupropion and amitriptyline in depressed inpatients. 
  • A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. 
  • A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. 
  • Adapting smoking cessation treatment according to initial response to precessation nicotine patch. 
  • Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care. 
  • An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. 
  • Appetite and weight in children treated for ADHD. 
  • Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. 
  • Bioequivalence and Therapeutic Equivalence of Generic and Brand Bupropion in Adults With Major Depression: A Randomized Clinical Trial. 
  • Brief Behavioral Therapy and Bupropion for Sleep and Fatigue in Young Adults With Crohn's Disease: An Exploratory Open Trial Study. 
  • Bupropion SR in the naturalistic treatment of elderly patients with major depression. 
  • Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. 
  • Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. 
  • Bupropion and Naltrexone in Methamphetamine Use Disorder. 
  • Bupropion and guanfacine. 
  • Bupropion dosing recommendations. 
  • Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. 
  • Bupropion in chronic low back pain. 
  • Bupropion in the treatment of outpatients with asthma and major depressive disorder. 
  • Bupropion sustained release: a therapeutic overview. 
  • Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. 
  • Bupropion-varenicline interactions and nicotine self-administration behavior in rats. 
  • Bupropion/zonisamide combination to assist smokers to switch from combustible cigarettes to electronic nicotine delivery systems (ENDS). 
  • Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. 
  • Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort. 
  • Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression. 
  • Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. 
  • Combination Varenicline/Bupropion Treatment Benefits Highly Dependent Smokers in an Adaptive Smoking Cessation Paradigm. 
  • Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. 
  • Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. 
  • Combining antidepressant medications: a good idea? 
  • Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. 
  • Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition. 
  • Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. 
  • Cost-effectiveness analysis of the first-line therapies for nicotine dependence. 
  • Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. 
  • D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell. 
  • Depression treatment in patients with general medical conditions: results from the CO-MED trial. 
  • Depression, IV: STAR*D treatment trial for depression. 
  • Design considerations for a study to evaluate the impact of smoking cessation treatment on stimulant use outcomes in stimulant-dependent individuals. 
  • Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma. 
  • Development, validation and application of a comprehensive stereoselective LC/MS-MS assay for bupropion and oxidative, reductive, and glucuronide metabolites in human urine. 
  • Dextromethorphan and bupropion reduces high level remifentanil self-administration in rats. 
  • Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. 
  • Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial. 
  • Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? 
  • Does Extended Pre Quit Bupropion Aid in Extinguishing Smoking Behavior? 
  • Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. 
  • Does pretreatment insomnia or anxiety predict acute response to bupropion SR? 
  • Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs. 
  • Effect of Extended Release Bupropion on Unilateral Ultrabrief Electroconvulsive Therapy Seizure Parameters in Major Depressive Disorder. 
  • Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. 
  • Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. 
  • Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. 
  • Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. 
  • Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. 
  • Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. 
  • Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. 
  • Forms of atypical depression and their response to antidepressant drugs. 
  • Functional status in depressed patients: the relationship to disease severity and disease resolution. 
  • Increase in work productivity of depressed individuals with improvement in depressive symptom severity. 
  • Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. 
  • Medication augmentation after the failure of SSRIs for depression. 
  • Misidentification of Bupropion Glucuronide Metabolites and Re-evaluation of Metabolite Pharmacokinetics. 
  • Mobile contingency management as an adjunctive smoking cessation treatment for smokers with posttraumatic stress disorder. 
  • Molecular genetics of successful smoking cessation: convergent genome-wide association study results. 
  • Multicomponent smoking cessation treatment including mobile contingency management in homeless veterans. 
  • New findings on nicotine addiction and treatment. 
  • Omission of bupropion as a recommended treatment for PTSD. 
  • Outcomes from an outpatient smoking-cessation clinic. 
  • Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. 
  • Patient-Informed Treatment Development of Behavioral Smoking Cessation for People With Schizophrenia. 
  • Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. 
  • Pharmacogenetics studies in STAR*D: strengths, limitations, and results. 
  • Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. 
  • Public health clinical demonstration project for smoking cessation in american veterans who served since september 11, 2001. 
  • Public health clinical demonstration project for smoking cessation in veterans with posttraumatic stress disorder. 
  • Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders. 
  • Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. 
  • Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program. 
  • Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. 
  • Recommendations for high-priority research on cancer-related fatigue in children and adults. 
  • Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. 
  • Response to Gorelick. 
  • Seizure associated with bupropion and guanfacine. 
  • Seizures and bupropion: a review. 
  • Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. 
  • Smoking quit success genotype score predicts quit success and distinct patterns of developmental involvement with common addictive substances. 
  • Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants. 
  • Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults. 
  • Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS. 
  • Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. 
  • Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes. 
  • Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort. 
  • Suicide in pregnancy. 
  • The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. 
  • The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. 
  • The use of pharmacotherapies for smoking cessation during pregnancy. 
  • Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density. 
  • Use of Prescription Smoking Cessation Medications After Myocardial Infarction Among Older Patients in Community Practice. 
  • Use of bupropion SR in a pharmacist-managed outpatient smoking-cessation program. 
  • Use of bupropion in combination with serotonin reuptake inhibitors. 
  • Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. 
  • What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. 
  • What predicts attrition in second step medication treatments for depression?: a STAR*D Report. 
  • What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study. 
  • Zyban: two products, two uses--too confusing?